Answers are grounded in this paper and cite their sources.
With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.
No takes yet. Share an insight, caveat, or question.
Reck et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: